Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody
View Patent ↗Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
1. A method of inducing apoptosis in a cancer cell, the method comprising contacting the cell with:
i. an anti-DR5 affinity agent agonist; and
ii. an apoptosis-inducing agent,
wherein the apoptosis-inducing agent comprises TRAIL,
wherein the anti-DR5 affinity agent agonist is an anti-DR5 antibody comprising the complementarity determining regions of SEQ ID NO: 8 and SEQ ID NO: 10, and wherein the anti-DR5 affinity agent agonist and the apoptosis-inducing agent act synergistically to induce apoptosis in cancer cells.
2. The method of claim 1 , wherein the agonist is a humanized antibody.
3. The method of claim 1 , wherein the agonist is a single chain antibody.
4. The method of claim 1 , wherein TRAIL is endogenous.
5. The method of claim 1 , wherein the apoptosis-inducing agent further comprises one or more additional apoptosis-inducing agents.
6. The method of claim 1 , wherein the cancer cell is a colon cancer cell or a pancreatic cancer cell.
7. A method of inducing apoptosis in a cancer cell in an individual in need thereof, the method comprising administering to the individual a therapeutically effective amount of:
i. an anti-DR5 affinity agent agonist; and
ii. an apoptosis-inducing agent,
wherein the apoptosis-inducing agent comprises TRAIL,
wherein the anti-DR5 affinity agent agonist is an anti-DR5 antibody comprising the complementarity determining regions of SEQ ID NO: 8 and SEQ ID NO: 10, and wherein the anti-DR5 affinity agent agonist and the apoptosis-inducing agent act synergistically to induce apoptosis in cancer cells.
8. The method of claim 7 , wherein (i) the anti-DR5 affinity agent agonist and (ii) the apoptosis-inducing agent are administered separately.
9. The method of claim 7 , wherein (i) the anti-DR5 affinity agent agonist and (ii) the apoptosis-inducing agent are administered as a mixture.
10. The method of claim 7 , wherein the agonist is a humanized antibody.
11. The method of claim 7 , wherein the agonist is a single chain antibody.
12. The method of claim 7 , wherein the apoptosis-inducing agent further comprises one or more additional apoptosis-inducing agents.
13. The method of claim 7 , wherein the cancer cell is a colon cancer cell or a pancreatic cancer cell.
14. A physiological composition comprising:
i. an anti-DR5 affinity agent agonist; and
ii. an apoptosis-inducing agent,
wherein the apoptosis-inducing agent comprises TRAIL,
wherein the anti-DR5 affinity agent agonist is an anti-DR5 antibody comprising the complementarity determining regions of SEQ ID NO: 8 and SEQ ID NO: 10, and wherein the anti-DR5 affinity agent agonist and the apoptosis-inducing agent act synergistically to induce apoptosis in cancer cells.
15. The physiological composition of claim 14 , wherein the agonist is a humanized antibody.
16. The physiological composition of claim 14 , wherein the agonist is a single chain antibody.
17. The composition of claim 14 , wherein the apoptosis-inducing agent further comprises one or more additional apoptosis-inducing agents.